GSK Enters into a 5-Year Partnership with Cambridge University to Address Kidney and Respiratory Diseases
Shots:
- GSK has signed a 5yrs. deal worth £50M with University of Cambridge and Cambridge University Hospitals named as Cambridge-GSK Translational Immunology Collaboration (CG-TIC)
- The goal is to improve existing precision therapies for immune-related diseases & accelerate new drug development by studying disease mechanisms, progression, therapy responses & developing translational biomarkers
- CG-TIC will utilize AI & ML to address hard-to-treat kidney & lung diseases, improving patient outcomes. Cambridge will offer environment to involve patients, with Cambridge University Hospitals playing a key role & Royal Papworth Hospital likely to be the future partner
Ref: GSK | Image: GSK
Related News:- GSK Reports the US FDA’s NDA Acceptance of Gepotidacin with Priority Review to Treat Uncomplicated Urinary Tract Infections
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
